Altimmune (ALT) Receivables - Net (2010 - 2026)

Altimmune (ALT) has 17 years of Receivables - Net data on file, last reported at $1.7 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $1.7 million, up 228.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 228.4% YoY), and the FY2025 annual result was $1.2 million, up 124.08% from the prior year.
• Receivables - Net advanced to $1.7 million in Q1 2026 per ALT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Receivables - Net peaked at $1.7 million in Q1 2026 and troughed at $136000.0 in Q2 2023.
• A 5-year average of $578176.5 and a median of $428000.0 in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net slumped 95.98% in 2022, then soared 542.2% in 2023.
• A 5-year view of Receivables - Net shows it stood at $173000.0 in 2022, then soared by 542.2% to $1.1 million in 2023, then plunged by 51.04% to $544000.0 in 2024, then soared by 124.08% to $1.2 million in 2025, then soared by 36.59% to $1.7 million in 2026.
• Business Quant data shows ALT's Receivables - Net at $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $845000.0 in Q3 2025.